TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14736927
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy (at least 240 mg/m²); 932 patients assigned to chemotherapy
Study: 9784911
Drug: Dipyridamole (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (300 mg/d) for 6 months
Study: 9784911
Drug: Dilazep (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilazep (300 mg/d) for 6 months
Study: 2832764
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with thoracic irradiation (protocol 78 LUN 328)
Study: 2832764
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with simultaneous radiotherapy (protocol LUN 81343)
Study: 2832764
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy alone (control group)
Study: 22332908
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg trans-resveratrol twice daily for 12 weeks
Study: 22332908
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg trans-resveratrol twice daily for 12 weeks
Study: 2145874
Drug: UK 69,578
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 69,578 (atriopeptidase inhibitor) administered as an intravenous infusion over 20 min
Study: 2145874
Drug: UK 69,578
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 69,578 (atriopeptidase inhibitor)
Study: 620911
Drug: Cimetidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (0.8 to 1.2 g daily for 2 to 6 weeks)
Study: 620911
Drug: Cimetidine therapy
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine therapy cessation
Study: 620911
Drug: Chronic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic or intermittent cimetidine therapy
Study: 27803139
Drug: TNF-α inhibitors
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF-α inhibitors (Infliximab and Etanercept)
Study: 24673513
Drug: Benvitimod (0.5-2.0%)
Normalized name: Benvitimod
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benvitimod (0.5-2.0%) cream, doses escalated from 5 to 30 mg daily, applied once or twice daily
Study: 24673513
Drug: Benvitimod (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benvitimod (5 mg q.d and b.i.d)
Study: 22988684
Drug: In-office treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office treatment with desensitizing paste containing 8% arginine and calcium carbonate, followed by brushing with desensitizing toothpaste containing 8% arginine, calcium carbonate with 1450 ppm fluoride for 24 weeks.
Study: 20174763
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment (overall)
Study: 17431110
Drug: Lonafarnib (Farnesyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lonafarnib (Farnesyl transferase inhibitor)
Study: 15867580
Drug: 5‐ASA MMx
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA MMx (1.2 g three times per day)
Study: 15867580
Drug: 5‐ASA enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA enema (4 g)
Study: 16679206
Drug: Long buccal-segment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long buccal-segment group (canines, both premolars, and first molars)
Study: 16679206
Drug: Short buccal-segment
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short buccal-segment group (only maxillary first molars)
Study: 10826565
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet with L-NMMA infusion (1.8 mg/kg over 30 min)
Study: 10826565
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet with L-NMMA infusion (1.8 mg/kg over 30 min)
Study: 8858747
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (5 g/day)
Study: 8858747
Drug: Carbohydrate-reduced diet
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-reduced diet (84 g/day)
Study: 6507509
Drug: Diuretics continued
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics continued throughout pregnancy
Study: 6507509
Drug: Diuretics discontinued
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics discontinued immediately
Study: 27463412
Drug: Low-lactose skimmed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-lactose skimmed milk enriched with 40 mg/100 mL of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA), 0.54 g/100 mL oleic acid, and vitamins (n = 63)
Study: 19609570
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity intervention (home-based aerobic and light resistance training program, weekly group sessions)
Study: 18756746
Drug: Structural resonance
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural resonance electromagnetic therapy (SREMT) in the basic group
Study: 18756746
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug and physiotherapeutic treatment
Study: 15925962
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine and Oral methadone
Study: 12872590
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment (100 mJ/pulse and 10 Hz)
Study: 12872590
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (untreated implants)
Study: 1906441
Drug: Chronic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chronic low-dose TRH therapy
Study: 30902753
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of oral tranexamic acid (TXA) 2 h preoperatively
Study: 30902753
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of oral tranexamic acid (TXA) 4 h postoperatively
Study: 30902753
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of oral tranexamic acid (TXA) at 4, 10, and 16 h postoperatively
Study: 23260261
Drug: Ranibizumab (RBZ)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (RBZ) 0.3 mg
Study: 23260261
Drug: Ranibizumab (RBZ)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (RBZ) 0.5 mg
Study: 23260261
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to 0.5 mg RBZ from sham at month 6
Study: 17644340
Drug: Encapsulated phytosterol
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated phytosterol esters (2.6 g for 12 weeks)
Study: 15100522
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol solution
Study: 11562614
Drug: Tobramycin for
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin for inhalation
Study: 8163364
Drug: Estraderm TTS
Normalized name: ESTRADERM TTS
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estraderm TTS 50 patches
Study: 28882773
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave treatment (ESWT) plus specific exercise programme
Study: 20673296
Drug: Partial implant-supported
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial implant-supported prosthesis
Study: 20673296
Drug: No implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: No implants (control group)
Study: 19262561
Drug: Caltrate D
Normalized name: Caltrate Plus D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caltrate D (1 pill daily)
Study: 15319704
Drug: Ropinirole (1.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (1.45 mg/d mean dosage)
Study: 15319704
Drug: Levodopa sustained
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa sustained release (190 mg/d mean dosage)
Study: 11167169
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion with fentanyl (19.2+/‐5.2 microg x h(‐1))
Study: 11167169
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion without fentanyl
Study: 9024025
Drug: Acupressure bands
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure bands + 2 mL IV saline
Study: 9024025
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg IV metoclopramide + placebo wrist bands
Study: 9024025
Drug: Placebo wrist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo wrist bands + 2 mL IV saline
Study: 8275615
Drug: Valaciclovir (256U87)
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valaciclovir (256U87) at doses from 100 to 1000 mg (single-dose study)
Study: 8275615
Drug: Valaciclovir (256U87)
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valaciclovir (256U87) at doses from 250 to 2000 mg (multiple-dose study)
Study: 3546605
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) therapy
Study: 23473238
Drug: Multimodal coma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal coma stimulation twice a day (50 minutes each session)
Study: 23473238
Drug: Conventional physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy twice daily
Study: 16935774
Drug: EGFR tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EGFR tyrosine kinase inhibitors
Study: 16935774
Drug: EGFR tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EGFR tyrosine kinase inhibitors plus aromatase inhibitors
Study: 16935774
Drug: Overexpression of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overexpression of Wnt genes and methylation of Wnt antagonists
Study: 15823768
Drug: Escin during
Normalized name: escin
DrugBank: Escin (DB15907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escin during second and third treatment periods
Study: 15823768
Drug: No escin
Normalized name: escin
DrugBank: Escin (DB15907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No escin (Control) during first and fourth treatment periods
Study: 15823768
Drug: Escin treatment
Normalized name: escin
DrugBank: Escin (DB15907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escin treatment
Study: 9647368
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg, maximum 20 mg)
Study: 22305632
Drug: ATORVA (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATORVA (10, 20, 40, or 80 mg)
Study: 18276803
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 0.14 mg/kg
Study: 18276803
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 0.3 mg/kg
Study: 16869815
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 10 mg
Study: 16467761
Drug: Single immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single immediate dose of Mitomycin C (MMC)
Study: 16467761
Drug: Delayed multi-dose
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed multi-dose regimen of Mitomycin C (MMC)
Study: 12830444
Drug: Conventional thrice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional thrice-weekly HD
Study: 12830442
Drug: Quotidian HD
Normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quotidian HD therapy
Study: 10706488
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled steroids
Study: 10706488
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose inhaled steroids
Study: 9322351
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o.
Study: 9322351
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o. + Dexamethasone 20 mg i.v. on days 1 + 2, then 4 mg i.v./p.o.
Study: 9322351
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o. + Metoclopramide 20 mg i.v. + 2 x 10 mg p.o. on day 1, then 3 x 10 mg p.o.
Study: 29198307
Drug: Quetiapine 25
Normalized name: quetiapine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 25 mg film-coated tablets
Study: 29198307
Drug: Control formulation
Normalized name: nut.tx, weight loss-control formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formulation of quetiapine 25 mg film-coated tablets
Study: 19133217
Drug: Maraviroc (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (300 mg, once or twice per day)
Study: 16364669
Drug: CS-003 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-003 (200 mg, solution in distilled water)
Study: 1564128
Drug: Once-a-day therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-a-day therapy (i.v. dose: 0.8-33 mg/kg; oral dose: 1.6-66 mg/kg)
Study: 1564128
Drug: Twice-a-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day therapy (i.v. dose: 0.8-33 mg/kg; oral dose: 1.6-66 mg/kg)
Study: 3721055
Drug: Intramuscular buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular buprenorphine (0.3 mg)
Study: 3544957
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine (75 mg)
Study: 20955603
Drug: Individualized, nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, nutritional treatment with energy- and protein-rich supplementation
Study: 14653300
Drug: bleaching with
Normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleaching with gel + 10% sodium ascorbate (SA)
Study: 14653300
Drug: bleaching with
Normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleaching with gel
Study: 14653300
Drug: bleaching with
Normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleaching with gel + 10% butylhydroxyanisole (BHA)
Study: 14653300
Drug: bleaching with
Normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleaching with gel + immersed in artificial saliva for seven days
Study: 7763124
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (2 mg/kg) and intravenous saline (5 mL/kg)
Study: 7763124
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline (2 mL) and intravenous 10% ethanol (5 mL/kg)
Study: 7763124
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (2 mg/kg) and intravenous 10% ethanol (5 mL/kg)
Study: 7763124
Drug: Intranasal (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (2 mL) and intravenous (5 mL/kg) saline
Study: 2106127
Drug: Furosemide treatment
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide treatment with high phosphorus intake (1.64 +/- 0.06 mmol/kg per day)
Study: 2106127
Drug: Furosemide treatment
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide treatment with moderate phosphorus intake (1.24 +/- 0.02 mmol/kg per day)
Study: 2106127
Drug: Furosemide treatment
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide treatment with low phosphorus intake (0.91 +/- 0.06 mmol/kg per day)
Study: 1278006
Drug: Furosemide treatment
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide treatment
Study: 26054881
Drug: Ubiquinol‐10 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol‐10 (300 mg per day for 48 weeks)
Study: 26054881
Drug: Ubiquinol‐10 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol‐10 (300 mg per day for 96 weeks)
Study: 23810276
Drug: Rosuvastatin/olmesartan 20/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin/olmesartan 20/40 mg (test formulation)
Study: 23810276
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg and olmesartan 40 mg (reference formulation)
Study: 21592475
Drug: Lamivudine in
Normalized name: Product containing lamivudine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine in the third trimester and postpartum antiviral treatment
Study: 21592475
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment only)
Study: 19848566
Drug: Tailored feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored feedback based on cholesterol-related knowledge, attitudes, beliefs, and perceived barriers to medication adherence; 2 additional tailored IVR support calls.
Study: 8251027
Drug: DL473 twice‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL473 twice‐weekly (2HE+L2/7H2L2)
Study: 8251027
Drug: ARFp twice‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARFp twice‐weekly (2HE+R2/7H2R2)
Study: 8251027
Drug: BRFP daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRFP daily (2HRE/7HR)
Study: 2883223
Drug: Oxytetracycline lavage
Normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytetracycline lavage plus peroperative intravenous metronidazole and cefuroxime
Study: 29265793
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac 75 mg + thiocolchicoside 4 mg (FDC)
Study: 29265793
Drug: Separate injection
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injection of diclofenac and thiocolchicoside (reference)
Study: 29265793
Drug: Both test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both test and reference treatments
Study: 23737940
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg zinc plus riboflavin 0.5 mg/day)
Study: 23737940
Drug: Placebo (riboflavin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (riboflavin 0.5 mg/day)
Study: 22980173
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of alprazolam
Study: 24385131
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of alprazolam
Study: 16631127
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of diphenhydramine (Benadryl)
Study: 16631127
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of alprazolam (1 mg)
Study: 10333379
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg QD)
Study: 8596376
Drug: CGP 39393
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 39393 (10 mg)
Study: 8596376
Drug: CGP 39393
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 39393 (15 mg)
Study: 8596376
Drug: CGP 39393
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 39393 (20 mg)
Study: 8596376
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 IU three times daily)
Study: 1822255
Drug: Atropine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (bolus dose 10 micrograms x kg‐1 followed by a constant-rate infusion of 0.02 microgram x kg‐1 x min‐1)
Study: 1822255
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of atropine (approximately 1.8‐1.9 mg)
Study: 22309507
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 0.4 ml · kg(‐1) plus clonidine 1 μg · kg(‐1) in 1 ml (RC)
Study: 22309507
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 0.4 ml · kg(‐1) plus saline in 1 ml (RS)
Study: 20235224
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers and cardiac glycosides
Study: 17667496
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/min infusion for 4 hours postoperatively)